Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia

The goal of this clinical trial is to learn if BiTE-EV works to treat relapsed/refractory acute B-cell leukemia in adults. It will also learn about the safety of BiTE-EV. The main questions it aims to answer are: Can BiTE-EV effectively treat relapsed/refractory acute B-cell lymphoblastic leukemia? What medical problems do participants have when taking BiTE-EV? Participants will: Take BiTE-EV every other day for 1 or 2 months Keep a diary of their symptoms during the medication period During the follow-up period, visit the clinic once every 4 weeks for checkups and tests

Trial Details

NCT ID
NCT06890494
Phase
EARLY_PHASE1
Sponsor
Beijing GoBroad Hospital
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • BiTE-EV
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients with acute B lymphocytic leukemia who are clinically diagnosed as relapsed (relapsed after CAR-T treatment or relapsed after transplantati…
  • Tumor cells show positive expression of CD19 detected by flow cytometry or immunohistochemistry.
  • The age is between 18 and 70 years old (inclusive).
  • The expected survival period from the date of signing the informed consent form is greater than 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →